Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and ...

New USD 130 million facility to focus on next-generation, sustainable solutions for farming Enhanced commitment to UK as a key hub for global R&D and innovation ...

Pulse Biosciences (Nasdaq:PLSE) announced a new strategic alignment to focus on its nPulse cardiac catheter ablation system.

Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.

Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibodyTechnology licensed from Gates MRI; early studies confirm suppression of RSV infectionTargeting ...

Nanosecond PFA Cardiac Surgical System for ablation of cardiac tissue to be highlighted in presentation and poster sessions. “We believe the Nanosecond PFA Cardiac Surgical System has the potential to ...

SK Bioscience said Wednesday it has secured funding from the Research Investment for Global Health Technology Foundation to advance the clinical development of ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...